Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Inauhzin is a cell-permeable, SIRT1 inhibitor (IC50 = 0.7-2 µM) that reactivates p53 by inhibiting SIRT1 deacetylation activity.1 It binds directly to SIRT1 and does not affect SIRT2, SIRT3, or HDAC8.1 Inauhzin has been shown to inhibit cell proliferation by inducing p53-dependent apoptosis in various human cancer cells (IC50s = 5.4, 51.9, 3.2, 33.9, and 85.4 µM for H460, H1299, A549, HT-29, and WI38 cells, respectively), as well as in xenograft tumors derived from H460 cells.1 It has also been shown to activate p53 synergistically with the Mdm2 inhibitor nutlin-3 (Item No. 10004372), sensitizing cancer cells to cisplatin (Item No. 13119) and doxorubicin (Item No. 15007).2
WARNING This product is not for human or veterinary use.
1. A small molecule Inauhzin inhibits SIRT1 activity and suppresses tumour growth through activation of p53. EMBO Mol. Med. 4(4), 298-312 (2012).
2. Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth. Cancer Biol. Ther. 13(10), 915-924 (2012).